株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

アフリカの医薬品市場:2020年までの予測

African Pharmaceuticals Market, Forecast to 2020

発行 Frost & Sullivan 商品コード 410387
出版日 ページ情報 英文 66 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.66円で換算しております。
Back to Top
アフリカの医薬品市場:2020年までの予測 African Pharmaceuticals Market, Forecast to 2020
出版日: 2016年12月21日 ページ情報: 英文 66 Pages
概要

アフリカの医薬品市場は2020年に450億米ドル規模になると見込まれています。変化する経済的プロファイル、急速な都市化、医療支出と投資の増加、慢性的生活習慣病の発症率上昇などが市場の拡大を推進しています。

当レポートでは、アフリカの医薬品市場について調査し、主にナイジェリアとケニアの医薬品市場の動向、セグメント別収益、法規制環境と競合動向などをまとめています。

第1章 エグゼクティブサマリー

第2章 市場概要

  • 概要
  • 主な製品とセグメント
  • 医療業界のメガトレンドがSSA医薬品市場に及ぼす影響
  • 医薬品輸入
  • 収益予測
  • アフリカの医薬品製造における課題
  • アフリカの医薬品サプライチェーンにおける課題

第3章 市場分析:ナイジェリア

  • 市場概要
  • 市場セグメンテーション:処方薬とOTC薬
  • 市場セグメンテーションと規模:ジェネリック薬とブランド薬
  • 処方薬市場:セグメント別収益
  • 処方薬市場:製品別収益率
  • OTC薬:セグメント別収益
  • 購買と調達
  • 医薬品市場動向
  • 市場促進因子
  • 市場阻害因子
  • 薬価分析
  • 法規制環境
  • 主要参入企業リスト
  • 競合因子と評価

第4章 市場分析:ケニア

  • 市場概要
  • 市場セグメンテーション:処方薬とOTC薬
  • 市場セグメンテーションと規模:ジェネリック薬とブランド薬
  • 処方薬市場:セグメント別収益
  • 処方薬市場:製品別収益率
  • OTC薬:セグメント別収益
  • 購買と調達
  • 医薬品市場動向
  • 市場促進因子
  • 市場阻害因子
  • 薬価分析
  • 法規制環境
  • 主要参入企業リスト
  • 競合因子と評価

第5章 結論と提言

  • 医薬品ポートフォリオの注目領域
  • 医薬品製造
  • 結論と提言

第6章 最後に

目次
Product Code: MC24-52

Assessing Market Potential with a Focus on Kenya and Nigeria

The pharmaceuticals market in Africa is expected to reach a business opportunity of $45 billion in 2020, propelled by a convergence of changing economic profiles, rapid urbanisation, increased healthcare spending and investment, and increasing incidence of chronic lifestyle diseases.

The tropical climate of Africa makes the continent the largest reservoir of infectious diseases, particularly malaria, tuberculosis (TB), and acquired immune deficiency syndrome (AIDS), besides frequent outbreaks of polio, meningitis, cholera, pandemic influenza, yellow fever, measles, hepatitis, and tetanus. With the increasing adoption of Western lifestyle in Africa, there has been a paradigm shift in the burden of illness towards non-communicable diseases (NCDs), driving the demand for chronic prescription drugs. While continuing to suffer from infectious and parasitic illness, lifestyle diseases such as cardiovascular diseases, diabetes, and cancer will witness high growth rates throughout the forecast period. The World Health Organisation predicts that the proportional contribution of NCDs to the healthcare burden in Africa will rise by 21% through 2030. The growing middle class is a key driving force for pharmaceuticals spending. Limited affordability of governments and the general population for healthcare and pharmaceuticals and a high reliance on donor funding will be the major market restraints.

Africa is in a transition phase, on its way to achieving adherence to global standards, such as the WHO pre-qualification for manufacturing. Local production is regarded as a key strategy for sustained access to quality-assured medicines for the long term. The regulatory environment for manufacturing in regions such as East Africa seems to grow rapidly, owing to regional harmonisation. Healthcare coverage is expected to expand to a greater proportion of the population through National Health Insurance (NHI) initiatives, as well as through memberships with private health insurance providers, particularly among the emerging middle class.

South Africa remains as the best established region for pharmaceutical manufacturing in sub-Saharan Africa. However, the local manufacturing markets in East and West Africa are relatively well developed and positioned to grow. A bulk of Africa-based pharmaceutical companies that are developing medicines have simple formulations and mixtures, which are easy to do. Technology transfer is paramount to developing the manufacturing sector in Africa, particularly as the disease burden is changing. There is a paradigm shift coming from the lower end to the higher end of adoption of complex formulations, in line with treatment guidelines, especially in HIV and AIDS and NCDs.

This research service presents findings on 2 fast-growing pharmaceutical markets in sub-Saharan Africa: Kenya and Nigeria. A brief competitive overview, along with the pricing and regulatory environment is provided for each country. Revenues and growth forecasts, insights on market dynamics, and drivers and restraints for the pharmaceutical markets of Kenya and Nigeria are covered. Market segmentation is done based on products (prescription-branded and generic and consumer care/over the counter) as well as therapeutic areas (haematology, oncology, men's health, central nervous system (CNS), women's health, diabetes, cardiovascular, dermatological, gastrointestinal, cough and cold, nutritional, analgesics, and anti-infectives).The study also provides the business opportunities and strategic recommendations for the pharmaceuticals market.

Table of Contents

1. EXECUTIVE SUMMARY

  • Market Themes
  • Key Findings

2. MARKET OVERVIEW

  • Overview
  • Overview (continued)
  • Key Products and Segments
  • Impact of Healthcare Industry Mega Trends on the SSA Pharmaceuticals Market
  • Pharmaceutical Imports
  • Revenue Forecast
  • Key Challenges in African Pharmaceuticals Manufacturing
  • Key Challenges in African Pharmaceuticals Supply Chain

3. MARKET ANALYSIS-NIGERIA

  • Market Overview
  • Market Segmentation-Prescription Vs OTC
  • Market Segmentation and Size-Generic Vs Branded
  • Prescription Market-Revenue Breakdown by Therapeutic Segments
  • Prescription Market-Percent Revenue Breakdown by Products
  • OTC Market-Revenue Breakdown by Therapeutic Segments
  • Purchasing and Procurement
  • Pharmaceuticals Market Trends
  • Market Drivers
  • Drivers Explained
  • Drivers Explained (continued)
  • Market Restraints
  • Restraints Explained
  • Restraints Explained (continued)
  • Pricing Analysis
  • Regulatory Environment
  • Regulatory Environment (continued)
  • Pharmaceuticals Market-List of Key Participants
  • Nigeria-Competitive Factors and Assessment

4. MARKET ANALYSIS-KENYA

  • Market Overview
  • Market Overview (continued)
  • Market Segmentation-Prescription Vs OTC
  • Market Segmentation and Size-Generic Vs Branded
  • Prescription Market-Revenue Breakdown by Therapeutic Segments
  • Prescription Market-Percent Revenue Breakdown by Products
  • OTC Market-Revenue Breakdown by Therapeutic Segments
  • Purchasing and Procurement
  • Pharmaceuticals Market Trends
  • Market Drivers
  • Drivers Explained
  • Drivers Explained (continued)
  • Market Restraints
  • Restraints Explained
  • Restraints Explained (continued)
  • Pricing Analysis
  • Regulatory Environment
  • Regulatory Environment (continued)
  • Pharmaceuticals Market-List of Key Participants
  • Kenya-Competitive Factors and Assessment

5. CONCLUSIONS AND RECOMMENDATIONS

  • Key Areas of Focus for Pharmaceutical Portfolio
  • Pharmaceutical Manufacturing
  • Conclusions and Recommendations

6. THE LAST WORD

  • The Last Word-3 Big Predictions
  • The Last Word-Discussion
  • Legal Disclaimer
  • Market Engineering Methodology
Back to Top